Last reviewed · How we verify
ALS-008176
At a glance
| Generic name | ALS-008176 |
|---|---|
| Sponsor | Alios Biopharma Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus (PHASE2)
- A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations (PHASE1)
- Study to Assess the Taste Profile of Different ALS-008176 Oral Liquid Formulations in Healthy Adult Participants (PHASE1)
- Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Participants (PHASE1)
- A Study of ALS-008176 in Infants Hospitalized With RSV (PHASE1)
- A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-64041575 in Adult Participants With Various Degrees of Renal Function (PHASE1)
- A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model (PHASE2)
- Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine Regimens in Adult Participants Hospitalized With Respiratory Syncytial Virus (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALS-008176 CI brief — competitive landscape report
- ALS-008176 updates RSS · CI watch RSS
- Alios Biopharma Inc. portfolio CI